


Accepted Manuscript

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer

Chun-Te Chiang, Alexandra N. Demetriou, Nolan Ung, Niharika Choudhury, Kimya Ghaffarian, Daniel L. Ruderman, Shannon M. Mumenthaler



PII: S0304-3835(18)30483-X

DOI: [10.1016/j.canlet.2018.07.025](https://doi.org/10.1016/j.canlet.2018.07.025)

Reference: CAN 13999

To appear in: *Cancer Letters*

Received Date: 8 May 2018

Revised Date: 17 July 2018

Accepted Date: 17 July 2018

Please cite this article as: C.-T. Chiang, A.N. Demetriou, N. Ung, N. Choudhury, K. Ghaffarian, D.L. Ruderman, S.M. Mumenthaler, mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.07.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer

Author Affiliations:

Chun-Te Chiang¹, Alexandra N. Demetriou¹, Nolan Ung¹, Niharika Choudhury¹, Kimya Ghaffarian¹, Daniel L. Ruderman¹, and Shannon M. Mumenthaler^{1*}

¹Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Los Angeles, California

* To whom correspondence should be addressed

Corresponding Author

S.M.: Department of Medicine, University of Southern California, 2250 Alcazar Street, CSC 242, Los Angeles, CA 90033. Phone: (323) 442-2529. E-mail: smumenth@usc.edu

Abstract

Non-small cell lung cancer (NSCLC) patients with activating *EGFR* mutations are often successfully treated with EGFR tyrosine kinase inhibitor (TKI) such as erlotinib; however, treatment resistance inevitably occurs. Given tumor metabolism of glucose and therapeutic response are intimately linked, we explored the metabolic differences between isogenic erlotinib-sensitive and -resistant NSCLC cell lines. We discovered that the growth of erlotinib-resistant cells is more sensitive to glucose deprivation. Seahorse metabolic assay revealed erlotinib-resistant cells have lower spare respiratory capacity (SRC), an indicator of metabolic flexibility, compared to erlotinib-sensitive cells. Additionally, we found downstream components of mTORC2 signaling to be phosphorylated in erlotinib-resistant cells. Knockdown of an mTORC2 component, Rictor, enhanced the SRC and rescued the growth rate of erlotinib-resistant cells during glucose deprivation. Among NSCLCs with activating *EGFR* mutations, gene sets involved in glucose metabolism were enriched in patients with high expression of p-NDGR1, a readout of mTORC2 activity. Furthermore, overall survival was negatively correlated with p-NDRG1. Our work uncovers a link between mTORC2 and metabolic reprogramming in EGFR TKI-resistant cells and highlights the significance of mTORC2 in the progression of *EGFR*-mutated NSCLC.

Key Words:

NSCLC, EGFR TKI resistance, glucose metabolism, mTORC2

Download English Version:

<https://daneshyari.com/en/article/8434135>

Download Persian Version:

<https://daneshyari.com/article/8434135>

[Daneshyari.com](https://daneshyari.com)